PL4055055T3 - Przeciwciała dwuswoiste przeciwko ceacam5 i cd47 - Google Patents

Przeciwciała dwuswoiste przeciwko ceacam5 i cd47

Info

Publication number
PL4055055T3
PL4055055T3 PL21834934.8T PL21834934T PL4055055T3 PL 4055055 T3 PL4055055 T3 PL 4055055T3 PL 21834934 T PL21834934 T PL 21834934T PL 4055055 T3 PL4055055 T3 PL 4055055T3
Authority
PL
Poland
Prior art keywords
antibodies against
bispecific antibodies
against ceacam5
ceacam5
bispecific
Prior art date
Application number
PL21834934.8T
Other languages
English (en)
Inventor
Vanessa BUATOIS
Anja SECKINGER
Dirk HOSE
Original Assignee
Lamkap Bio Beta Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lamkap Bio Beta Ag filed Critical Lamkap Bio Beta Ag
Publication of PL4055055T3 publication Critical patent/PL4055055T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Pens And Brushes (AREA)
  • Conversion Of X-Rays Into Visible Images (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL21834934.8T 2020-12-18 2021-12-17 Przeciwciała dwuswoiste przeciwko ceacam5 i cd47 PL4055055T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20215766 2020-12-18
US202163135996P 2021-01-11 2021-01-11
PCT/IB2021/061983 WO2022130348A1 (en) 2020-12-18 2021-12-17 Bispecific antibodies against ceacam5 and cd47

Publications (1)

Publication Number Publication Date
PL4055055T3 true PL4055055T3 (pl) 2024-04-15

Family

ID=79164846

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21834934.8T PL4055055T3 (pl) 2020-12-18 2021-12-17 Przeciwciała dwuswoiste przeciwko ceacam5 i cd47

Country Status (17)

Country Link
US (2) US11753481B2 (pl)
EP (1) EP4055055B1 (pl)
JP (1) JP2024501809A (pl)
KR (1) KR20230121772A (pl)
AU (1) AU2021400227A1 (pl)
CA (1) CA3193210A1 (pl)
CL (1) CL2023001797A1 (pl)
CO (1) CO2023009100A2 (pl)
ES (1) ES2967381T3 (pl)
HR (1) HRP20240213T1 (pl)
HU (1) HUE065728T2 (pl)
IL (1) IL301701A (pl)
MX (1) MX2023007220A (pl)
PE (1) PE20231386A1 (pl)
PL (1) PL4055055T3 (pl)
RS (1) RS65211B1 (pl)
WO (1) WO2022130348A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7403479B2 (ja) * 2018-06-03 2023-12-22 ランカプ バイオ ベータ リミテッド Ｃｅａｃａｍ５およびｃｄ４７に対する二重特異性抗体
RS65211B1 (sr) 2020-12-18 2024-03-29 Lamkap Bio Beta Ag Bispecifična antitela protiv ceacam5 i cd47
WO2023170474A1 (en) * 2022-03-07 2023-09-14 Novimmune Sa Cd28 bispecific antibodies for targeted t cell activation
US12122850B2 (en) * 2022-03-14 2024-10-22 LamKap Bio gamma AG Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells
KR20250025384A (ko) 2022-06-16 2025-02-21 람카프 바이오 베타 엘티디. Ceacam5 및 cd47에 대한 이중특이적 항체 및 ceacam5 및 cd3에 대한 이중특이적 항체의 조합 요법
WO2025100827A1 (ko) * 2023-11-09 2025-05-15 주식회사 다안바이오테라퓨틱스 항 ceacam5 항체 및 이의 용도

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294372B1 (en) 1997-03-14 2001-09-25 University Of Victoria Innovation & Dev. Corp. Replication genes and gene products from small cryptic plasmids and methods for constructing controlled-replication plasmid vectors
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2003265522A1 (en) 2003-08-18 2005-03-10 Macrogenics, Inc. FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
NZ545776A (en) 2003-08-22 2009-05-31 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
JP2007512846A (ja) 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
MXPA06012601A (es) 2004-05-10 2007-05-10 Macrogenics Inc Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos.
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
CN103172731A (zh) 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
WO2006023420A2 (en) 2004-08-16 2006-03-02 Medimmune, Inc. Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
EP1871808A2 (en) 2005-03-31 2008-01-02 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
WO2006116260A2 (en) 2005-04-26 2006-11-02 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
US7557190B2 (en) 2005-07-08 2009-07-07 Xencor, Inc. Optimized proteins that target Ep-CAM
CA2618681C (en) 2005-08-10 2015-10-27 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
AU2006299429B2 (en) 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
US7973136B2 (en) 2005-10-06 2011-07-05 Xencor, Inc. Optimized anti-CD30 antibodies
JP5328019B2 (ja) 2005-10-21 2013-10-30 レヴォ バイオロジクス インコーポレイテッド 抗体依存性細胞障害活性を増強させた抗体、その調製法および使用法
WO2007071426A1 (en) 2005-12-21 2007-06-28 Micromet Ag Pharmaceutical compositions with resistance to soluble cea
JP2009529331A (ja) 2006-03-10 2009-08-20 マクロジェニクス，インコーポレーテッド 変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法
IL177158A0 (en) 2006-07-30 2008-01-20 Assaf Klar Method for designing and implementing improved longitudinal flexibility multilayered pipeline
JP5825756B2 (ja) 2006-08-14 2015-12-02 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ１９を標的とする最適化抗体
WO2008036688A2 (en) 2006-09-18 2008-03-27 Xencor, Inc. Optimized antibodies that target hm1.24
WO2008121160A2 (en) 2006-11-21 2008-10-09 Xencor, Inc. Optimized antibodies that target cd5
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
WO2008091798A2 (en) 2007-01-22 2008-07-31 Xencor, Inc. Optimized ca9 antibodies and methods of using the same
WO2008091954A2 (en) 2007-01-23 2008-07-31 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
WO2008098115A2 (en) 2007-02-07 2008-08-14 Xencor, Inc. Optimized igf-1r antibodies and methods of using the same
DK2176298T3 (en) 2007-05-30 2018-02-12 Xencor Inc Methods and compositions for inhibiting CD32B-expressing cells
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
EP2242773B1 (en) 2008-02-11 2017-06-14 Cure Tech Ltd. Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
ES2458541T5 (en) 2008-05-02 2025-08-04 Seagen Inc Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
RS54233B1 (sr) 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
EP2328920A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Targeted costimulatory polypeptides and methods of use to treat cancer
WO2010033736A1 (en) 2008-09-17 2010-03-25 Xencor, Inc. Novel compositons and methods for treating ige-mediated disorders
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
EP2478110B1 (en) 2009-09-16 2016-01-06 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
US8642292B2 (en) 2009-09-22 2014-02-04 Probiogen Ag Process for producing molecules containing specialized glycan structures
RU2608640C2 (ru) 2010-08-16 2017-01-23 Новиммун С.А. Способы получения мультиспецифичных и мультивалентных антител
BR112013021460B1 (pt) 2011-03-02 2022-12-20 Roche Glycart Ag Anticorpos, composição e uso do anticorpo
WO2013012414A1 (en) 2011-07-18 2013-01-24 Medimmune, Llc Dosing regimens for treatment of cea-expressing cancers
EA026924B1 (ru) 2011-08-01 2017-05-31 Дженентек, Инк. Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
WO2013088259A2 (en) 2011-10-19 2013-06-20 Novimmune S.A. Methods of purifying antibodies
US20140140989A1 (en) 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
US9212224B2 (en) 2012-05-15 2015-12-15 Bristol-Myers Squibb Company Antibodies that bind PD-L1 and uses thereof
JP6392770B2 (ja) 2012-12-03 2018-09-19 ノビミューン エスアー 抗ｃｄ４７抗体およびその使用方法
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
WO2014131711A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
UA119320C2 (uk) 2013-02-26 2019-06-10 Рош Глікарт Аг Активуюча т-клітини біспецифічна антигензв'язувальна молекула
JP6586087B2 (ja) 2013-08-20 2019-10-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｐｄ−１アンタゴニストとジナシクリブとの組合せでの癌治療
EP3096782A4 (en) 2014-01-21 2017-07-26 Medlmmune, LLC Compositions and methods for modulating and redirecting immune responses
BR112017000497B1 (pt) 2014-07-11 2023-12-26 Ventana Medical Systems, Inc Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
PT3277821T (pt) 2015-03-31 2019-10-31 Novimmune Sa Método para otimizar a montagem e produção de complexos proteicos hetero-multiméricos
KR20180073561A (ko) 2015-10-02 2018-07-02 에프. 호프만-라 로슈 아게 이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자
GB2546072B (en) 2016-01-05 2019-07-10 Bja Trading Ltd Attachment assembly and method of using same
AR107303A1 (es) 2016-01-08 2018-04-18 Hoffmann La Roche Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
AR112048A1 (es) 2016-05-09 2019-09-18 Celgene Corp Anticuerpos cd47 y métodos de uso de los mismos
US11673971B2 (en) 2016-09-23 2023-06-13 Marengo Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
WO2018098384A1 (en) 2016-11-22 2018-05-31 Regents Of The University Of California Segregation modulation for immunotherapy
AU2018264321B2 (en) 2017-05-08 2025-03-06 Shanghai Jmt-Bio Technology Co., Ltd. Bispecific recombinant protein and use thereof
WO2019016411A1 (en) 2017-07-21 2019-01-24 Novimmune Sa GENERATION OF MULTISPECIFIC ANTIBODY MIXTURES AND METHODS OF USE
JP7403479B2 (ja) * 2018-06-03 2023-12-22 ランカプ バイオ ベータ リミテッド Ｃｅａｃａｍ５およびｃｄ４７に対する二重特異性抗体
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
RS65211B1 (sr) 2020-12-18 2024-03-29 Lamkap Bio Beta Ag Bispecifična antitela protiv ceacam5 i cd47

Also Published As

Publication number Publication date
AU2021400227A1 (en) 2023-04-27
HUE065728T2 (hu) 2024-06-28
WO2022130348A1 (en) 2022-06-23
CA3193210A1 (en) 2022-06-23
EP4055055A1 (en) 2022-09-14
US20240101705A1 (en) 2024-03-28
KR20230121772A (ko) 2023-08-21
AU2021400227A9 (en) 2024-05-30
CL2023001797A1 (es) 2024-02-09
IL301701A (en) 2023-05-01
JP2024501809A (ja) 2024-01-16
CO2023009100A2 (es) 2023-08-18
HRP20240213T1 (hr) 2024-04-26
EP4055055B1 (en) 2023-11-22
PE20231386A1 (es) 2023-09-12
MX2023007220A (es) 2023-08-25
ES2967381T3 (es) 2024-04-30
US11753481B2 (en) 2023-09-12
EP4055055C0 (en) 2023-11-22
RS65211B1 (sr) 2024-03-29
US20220195067A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
HUE065728T2 (hu) CEACAM5 és CD47 elleni bispecifikus antitestek
IL291482A (en) Bispecific antibodies against ceacam5 and cd3
EP3802599C0 (en) BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47
EP4010378A4 (en) ANTICCR8 MONOCLONAL ANTIBODIES AND USES THEREOF
SI3872091T1 (sl) Protitelesa proti SARS-COV-2
ZA202208807B (en) Anti-tigit antibodies and usage method
DK3823664T3 (da) Bispecifikke anti BCMA-X-anti CD3-antistoffer og anvendelser deraf
ZA202105150B (en) Conjugate comprising ligand and ceacam5 antibody fab fragment
SG11202012137UA (en) Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies
LT4274851T (lt) Anti-gprc5d monokloniniai antikūnai ir jų panaudojimas
IL307519A (en) Antibodies against ILT4, anti-ILT4\PD-L1 bispecific antibody and their uses
IL310662A (en) Anti-CD161 antibodies and their uses
EP3988574A4 (en) AGAINST HER2 BI-SPECIFIC ANTIBODIES AND THEIR USE
IL307940A (en) Anti-ADGRE2 antibodies and their uses
IL291082A (en) Anti-vsig4 antibody or antigen-binding fragment and uses thereof
EP4382541A4 (en) BISPECIFIC ANTIBODY AND USE THEREOF
IL291049A (en) Anti-cd47 monoclonal antibody and use thereof
EP4004054A4 (en) ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODIES AND ITS APPLICATION
IL315888A (en) Transgenic CD200R antibodies and their uses
TWI799855B (zh) 抗新型冠狀病毒(SARS-CoV-2)之新穎單株抗體及其應用
IL314678A (en) Bispecific antibodies against cd277 and a tumor-antigen
IL285569A (en) Anti-pd-l1 antibody and use thereof
EP4303231A4 (en) BISPECIFIC ANTIBODY
IL272733A (en) Monoclonal antibodies against pathological alpha-synuclein, and methods using same
IL307939A (en) Anti-CLEC12A antibodies and uses thereof